YS Biopharma Co., Ltd.

Equities

YS

KYG9845F1090

Pharmaceuticals

Delayed Nasdaq 20:54:22 20/05/2024 BST 5-day change 1st Jan Change
0.9824 USD +0.46% Intraday chart for YS Biopharma Co., Ltd. +9.13% +92.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023 CI
YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment MT
YS Biopharma Co., Ltd. Grants Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine CI
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of Pika Rabies Vaccine CI
YS Biopharma Co., Ltd. Announces Board Changes CI
YS Biopharma Co., Ltd. Announces Board Changes CI
YS Biopharma Co Announces the Results of Extraordinary General Meeting CI
YS Biopharma Co., Ltd. Announces Board Resignations CI
YS Biopharma Co., Ltd. Announces Chief Executive Officer Changes CI
YS Biopharma Co., Ltd. Announces Chief Financial Officer Changes CI
YS Biopharma Co., Ltd. Announces Management Changes CI
YS Biopharma Receives a Notice from APEX Prospect Limited CI
YS Biopharma Co., Ltd. Announces Appointment of New Directors CI
Ys Biopharma Co., Ltd. Announces Board Resignations CI
YS Biopharma Co., Ltd. announced that it expects to receive $39.999962 million in funding CI
YS Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2023 CI
YS Biopharma Co., Ltd. Appoints Rui Yu as Chairperson of Its Audit Committee, as Member of Its Compensation Committee, and as Member of the Nominating and Corporate Governance Committee CI
YS Biopharma Co., Ltd. Announces Board Changes CI
Noble Capital Initiates YS Biopharma With Outperform Rating, $5.25 Price Target MT
YS Biopharma Co., Ltd. Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine CI
YS Biopharma Enrolls 1st Subject in Late-Stage Rabies Vaccine Clinical Trial; Shares Rise MT
YS Biopharma Co., Ltd. Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine CI
YS Biopharma Says it Obtained US Patent for Immunotherapy Targeting Chronic Hepatitis B; Shares Gain Pre-Bell MT
Ys Biopharma Co., Ltd. Grants Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection CI
Sector Update: Health Care Stocks Climbing Late Afternoon MT
Chart YS Biopharma Co., Ltd.
More charts
YS Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.062 CNY
Average target price
29.98 CNY
Spread / Average Target
+324.53%
Consensus
  1. Stock Market
  2. Equities
  3. YS Stock
  4. News YS Biopharma Co., Ltd.
  5. Noble Capital Initiates YS Biopharma With Outperform Rating, $5.25 Price Target